Nasdaq Giant Goes All-In on XRP: SEC Filing Reveals Bold Payments & Treasury Strategy

Wall Street meets crypto—again. This time, it's a Nasdaq-listed player doubling down on XRP for its payment infrastructure and treasury reserves. The SEC filing drops just as the token claws back from its regulatory bruises.

Why XRP? Speed, cost, and a middle finger to legacy rails. While banks still argue about SWIFT upgrades, this firm's already executing cross-border settlements at a fraction of the time and cost. Their treasury move? Either a masterstroke or a gamble—depending on which crypto skeptic you ask.

One thing's clear: institutions aren't waiting for perfect regulatory clarity. They're building. And if this bet pays off, expect a stampede of copycats chasing those sub-3-second transaction times.

Meanwhile, Bitcoin maximalists are muttering about 'real decentralization' over their $50 coffees—paid for via Lightning Network, naturally.

In the latest XRP news, Wellgistics Health, Inc. (NASDAQ: WGRX) disclosed on July 24, 2025, that it will use the XRP cryptocurrency and XRP Ledger (XRPL) for real-time payments and treasury reserves.

The SEC FORM S-1 filing details plans to build an XRPL-based payment platform for near-instant, low-cost transactions across its pharmacy-manufacturer network.

The XRP news comes as Wellgistics shares trade around $0.94 with a market capitalization of roughly $58 million, down about 75% from its $234 million IPO value of Feb. 21, 2025.

XRP News: XRP Integration in SEC Filing

The S-1 registration statement lays out a multi‑phase strategy to deploy XRP. Wellgistics said it will implement an XRPL payment rail by Q3 2025.

This was to handle real-time, low-fee payments among its 6,000 pharmacies and 150 manufacturers.

The filing notes that XRP will not sit idle on the balance sheet, but will be actively used. The company plans to “accumulate XRP” with no fixed target, funding buys via equity or debt offerings.

Management intends to use XRP tokens as collateral for financing, to generate yield (e.g., staking or lending), and even to raise new capital for buying more XRP. In other words, XRP is treated as a Core financial instrument, not just a passive reserve.

According to XRP news, Wellgistics explained why it chose XRP. The asset settles in 3–5 seconds (versus 1–3 days for ACH/wires) and costs roughly $0.0002 per transfer (vs $10–$30 for a bank wire).

Its public ledger ensures full auditability of transactions, and it supports near‑zero fee cross-border payments. The company also noted that XRPL can underpin pharmacy credit lines and rebates.

CEO Brian Norton said the firm is “betting on infrastructure… not inertia” by hardwiring speed, transparency, and liquidity into healthcare payments.

Wellgistics’ Treasury and Capital Strategy

Wellgistics’ SEC filing explicitly treats XRP as a treasury asset. The company will use a newly secured $50 million equity line of credit from LDA Capital to fund its XRP program.

Under that agreement, Wellgistics can issue shares to LDA as needed for capital.

The filing indicates the firm may sell XRP holdings sparingly (to meet tax or cash needs) but otherwise hold them as a reserve and collateral pool.

As per the XRP news, it even contemplates paying out XRP “premiums” as incentives or rebates. In sum, the plan is to treat XRP as both a payment fuel and a balance-sheet asset, extracting income through yield strategies while using it to secure funding at potentially lower cost.

The S-1 acknowledges the risks: it notes that XRP’s regulatory status is unsettled, citing the paused SEC–Ripple appeal and recent $50 M settlement in May 2025, and warns that adverse outcomes could affect the token’s value.

Nonetheless, Wellgistics views the rewards as outweighing the uncertainty. The filing also references broader industry momentum like new XRP futures and partnerships, as justification for moving forward.

Financial Position and Stock Performance

Financially, Wellgistics is still small and pre‑profit. Its March 31, 2025 balance sheet shows $2.52 million in cash, $46.66 million in paid-in capital and a $42.19 million accumulated deficit (total stockholders’ equity $4.48 M).

Net tangible book value was –$40.9 M (–$0.79/share) at that date. In short, the company is cash‑poor, debt‑light (aside from an existing $1.3 M note), and has yet to generate significant revenue; it lost roughly $0.52 M in 2023 (on $0.34 M sales) in one of its subsidiaries.

Following the XRP news, former SEC official Marc Fagel raised concerns about Wellgistics Health’s credibility, citing its weak financials, lack of assets, and an auditor’s “going concern” warning.

He likened the company’s actions to crypto pump-and-dump schemes and questioned the need for a healthcare startup to hold significant crypto reserves.

Fagel suggested the XRP strategy might be a tactic to attract capital by capitalizing on the crypto and AI trends.